GSK accelerates transformation with M&A and pipeline growth under new CEO, offering attractive investment potential.

GSK is speeding up its strategic transformation under new CEO Luke Miels by focusing on mergers and acquisitions, expanding its drug pipeline, and managing its HIV franchise proactively. The company plans to start over 20 Phase III clinical trials in 2026 and is reinvesting GBP 1.9 billion in annual cost savings into research, development, and acquisitions to counteract the impact of upcoming HIV patent expirations. Although the turnaround is not yet complete, management is actively addressing risks related to its pipeline, margins, and HIV transition, making GSK an appealing buy for investors willing to accept some execution risk at a valuation of about 7 times next twelve months EV/EBITDA.

GSK trades at USD 47.12 with a 1.12% gain as of Oct 07, 2026 22:02 WIB on Pluang, showing positive investor response amid its strategic transformation. The stock's market cap stands at $93.51 billion, with a dividend yield of 3.9%, indicating steady income potential. Despite the article's focus on growth initiatives, Pluang order activity is currently 100% Sell, reflecting cautious sentiment among platform users.